Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | ENPP1 | P22413 | 4/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ENPP3 | O14638 | 3/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4168930 | 0.85 | TDP1 (0.57) | PKMENPP1MEN1KMT2ACA2 | |
| SCHEMBL3841654 | 0.82 | ENPP1 (0.53) | ENPP1PPARGMEN1KMT2ACA12 | |
| SCHEMBL9852204 | 0.82 | MEN1 (0.60) | ENPP1PPARGMEN1KMT2ACA12 | |
| SCHEMBL4126086 | 0.82 | MEN1 (0.60) | ENPP1PPARGMEN1KMT2ACA12 | |
| SCHEMBL18179825 | 0.82 | MEN1 (0.60) | ENPP1PPARGMEN1KMT2ACA12 | |
| SCHEMBL13401128 | 0.81 | ALDH1A1 (0.46) | PKMMEN1KMT2ACA2ALDH1A1 | |
| SCHEMBL8499355 | 0.81 | ENPP1 (0.55) | ENPP1PPARGMEN1KMT2ACA12 | |
| SCHEMBL15468472 | 0.81 | ENPP1 (0.55) | ENPP1PPARGMEN1KMT2ACA12 | |
| SCHEMBL2787389 | 0.80 | LMNA (0.45) | ENPP1MEN1KMT2AALDH1A1MAPT | |
| Iodide SCHEMBL22068772 | 0.80 | CA2 (0.59) | ENPP1PPARGMEN1KMT2ACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8487109-B2 | Process for the palladium-catalyzed coupling of terminal alkynes with aryl tosylates | SANOFI (FR) | 2013-07-16 | — | — | US | disclosed |
| EP-2176203-B1 | A PROCESS FOR THE PALLADIUM-CATALYZED COUPLING OF TERMINAL ALKYNES WITH ARYL TOSYLATES | SANOFI SA (FR) | 2011-08-10 | — | — | EP | disclosed |
| US-20100261910-A1 | Process for the palladium-catalyzed coupling of terminal alkynes with aryl tosylates | SANOFI-AVENTIS (FR) | 2010-10-14 | — | — | US | disclosed |
| EP-2176203-A1 | A PROCESS FOR THE PALLADIUM-CATALYZED COUPLING OF TERMINAL ALKYNES WITH ARYL TOSYLATES | Sanofi-Aventis (FR) | 2010-04-21 | — | — | EP | disclosed |
| WO-2009003589-A1 | A PROCESS FOR THE PALLADIUM-CATALYZED COUPLING OF TERMINAL ALKYNES WITH ARYL TOSYLATES | SANOFI-AVENTIS (FR) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261910-A1 | Process for the palladium-catalyzed coupling of terminal alkynes with aryl tosylates | TYR, ALK, TYRO3 | PKM 2263/4885ENPP1 1224/4885PPARG 3363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.